Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 22 resultados

SECRET: Exploring the therapeutic potential of perinatal cell SECRETomes Over the past two decades, cells isolated from human perinatal (or birth-associated) tissues (amniotic membrane, umbilical cord tissue and c...
2024-07-16 - 2028-08-31 | Financiado

MENTOR: Metabolic control of cell growth by mTOR in health and disease a multi disciplinary training MENTOR is a multi-disciplinary training network which focuses on the mTOR pathway, a central mechanistic hub that integrates nutritional cue...
2024-07-09 - 2028-12-31 | Financiado

MIRACLE: Integrated multi angle research and training network to eradicate leukemia minimal residual disease An estimated 300,000 new cases of leukemia are diagnosed each year globally. The most common form of acute leukemia is acute myeloid leukemi...
2024-06-28 - 2028-11-30 | Financiado

ARDAT: Accelerating Research Development for Advanced Therapies MIMETAS BV participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Major current hurdles for wide clinical use of AAV vectors are attributable primarily to: (i) host elimination by both immune and non-immune...
2020-11-11 - 2025-10-31 | Financiado

PRECODE: PancREatic Cancer OrganoiDs rEsearch Network MIMETAS BV participó en un H2020: H2020-MSCA-ITN-2019 The PRECODE Network (PancREatic Cancer OrganoiDs rEsearch) central mission is to establish pancreatic organoid research firmly in the Europe...
2019-08-12 - 2024-03-31 | Financiado

ENTRAIN: ENdoThelial macRophage Alliance In Neuroinflammation MIMETAS BV participó en un H2020: H2020-MSCA-ITN-2018 Neurological diseases cause enormous suffering and a great economic burden. Almost 20 million Europeans are affected by the most frequently...
2019-05-07 - 2023-04-30 | Financiado

TUBE: Transport derived Ultrafines and the Brain Effects MIMETAS BV participó en un H2020: H2020-MG-2018-2019-2020 The aim of the research is to study the effects of smallest traffic related ultrafine- or nanoparticles beyond the lung on brain health. Ai...
2019-04-11 - 2023-10-31 | Financiado

PD-MitoQUANT: PD MitoQUANT A quantitative approach towards the characterisation of mitochondrial dysfunction in... MIMETAS BV participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Mitochondrial dysfunction is implicated in Parkinson’s Disease (PD), but detailed understanding of the cause and effect in αSyn toxicity is...
2019-02-19 - 2022-07-31 | Financiado

OrganoPlate Graft: Organ on a Chip technology for in vitro grafting and vascularisation of 3D tissues MIMETAS BV tramitó un H2020: H2020-EIC-SMEInst-2018-2020 PROBLEM – The drug development cycle, from basic research to testing efficacy, toxicity, and safety of new therapeutics, is largely dependin...
2019-02-08 - 2022-02-28 | Financiado

IM2PACT: Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics IM2PACT Into The B... MIMETAS BV participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery...
2018-12-14 - 2024-12-31 | Financiado

FunHoMic: Deciphering the fungus host microbiota interplay to improve the management of fungal infections MIMETAS BV participó en un H2020: H2020-MSCA-ITN-2018 Fungal infections have a major impact on human health, infecting about 2 billion people and killing more people each year than malaria or br...
2018-09-13 - 2023-06-30 | Financiado

PoLiMeR: Polymers in the Liver Metabolism and Regulation MIMETAS BV participó en un H2020: H2020-MSCA-ITN-2018 Metabolic diseases are a burden on the European population and health care system. It is increasingly recognised that individual differences...
2018-08-20 - 2023-09-30 | Financiado

LOGIC LAB: Molecular logic lab on a vesicle for intracellular diagnostics MIMETAS BV participó en un H2020: H2020-MSCA-ITN-2018 A dysfunction of cells lining the inner walls of blood vessels, i.e. the endothelium, is the primary cause of many lifestyle related disease...
2018-08-17 - 2023-10-31 | Financiado

GLIOTRAIN: Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational... MIMETAS BV participó en un H2020: H2020-MSCA-ITN-2017 Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patien...
2017-08-29 - 2021-08-31 | Financiado

iPLACENTA: Innovation in modelling Placenta for Maternal and Fetal Health MIMETAS BV participó en un H2020: H2020-MSCA-ITN-2017 The placenta is the least understood human organ but arguably one of the most important-NIH Human Placenta Project . Innovation in Modelli...
2017-08-10 - 2022-05-31 | Financiado

ADAPTED: Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development Sofia ref.... MIMETAS BV participó en un H2020: H2020-JTI-IMI2-2015-05-two-stage APOEɛ4 has long been known as a risk factor of LOAD, yet the biological mechanisms through which it acts remain largely unknown and affect b...
2016-11-09 - 2020-09-30 | Financiado

CoSTREAM: Common mechanisms and pathways in Stroke and Alzheimer s disease. MIMETAS BV participó en un H2020: H2020-PHC-2014-2015 Common mechanisms and pathways in Stroke and Alzheimer's disease. It has long been recognized that stroke and (Alzheimer’s Disease) AD often...
2015-12-09 - 2021-05-31 | Financiado

SysMedPD: Systems Medicine of Mitochondrial Parkinson s Disease MIMETAS BV participó en un H2020: H2020-PHC-2014-2015 The overall objective of this project is to identify novel drug candidates capable of slowing down the progression of neurodegeneration in t...
2015-12-01 - 2020-11-30 | Financiado

MIMIC: Mimicking organs on chips for high throughput drug screening and basic research MIMETAS BV participó en un H2020: H2020-MSCA-ITN-2015 MIMIC is an interdisciplinary European Industrial Doctorate at the interface of cell biology, engineering and drug development. MIMIC aims t...
2015-06-15 - 2019-12-31 | Financiado